China once had a reputation for punching below its weight when it came to biotech. These days, however, the country is a rapidly growing hotbed for biopharma investment and activity. The sector there is churning out news at a dizzying clip, generating excitement about a coming wave of new therapies — as well as concerns about whether China’s ecosystem is ready to handle it all.
To keep up with the latest about biotech in China, join a subscriber-only online chat with STAT reporter Rebecca Robbins, who has been closely covering the sector’s rise. Rebecca will address investment trends, drug pricing and reimbursement, Hong Kong’s quest to become a destination for biotech listings, and the most important data readouts and regulatory decisions to watch for this fall.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
